feedback

Course Director

Kurt Schalper, MD, PhD
Kurt Schalper, MD, PhD

Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

Faculty

Edward B. Garon
Edward B. Garon, MD, MS

UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC
Credit Amount:1.0 Credits
Release Date:2018-Nov-30
Expiration Date:2019-Nov-29
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, experts in cancer immunotherapy discuss the role of current and emerging immuno-oncology biomarkers, including PD-L1 expression, MSI/MMR status, and TMB status, in predicting benefit from cancer immunotherapies, as well as practical considerations related to testing and interpretation of results to guide clinical decisions for patients with cancer.

Upon completion of this activity, participants should be better able to:
  • Summarize the basic principles of harnessing the human immune system in the treatment of cancer and the mechanistic aspects of immune checkpoint inhibition in cancer therapy
  • Review the clinical data on the efficacy and safety of immunotherapies and combinations across different tumors
  • Evaluate the evidence supporting the use of current and emerging biomarkers as predictors of benefit from cancer immunotherapies
  • Discuss practical aspects of immunotherapy biomarker testing and interpretations, including benefits/limitations of different testing methodologies, assays, cut-points, and other key considerations
  • Implement best practices for cancer immunotherapy biomarker testing based on the latest evidence and recommendations as well as effective interdisciplinary collaboration

Target Audience

This activity has been designed to meet the educational needs of pathologists and other healthcare professionals interested in precision immuno-oncology and immunotherapy biomarkers and/or those involved in cancer immunotherapy biomarker testing.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 30, 2018 - November 29, 2019
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC activity during the past 12 months.

Course Directors and Moderators

Kurt Schalper, MD, PhD
Assistant Professor of Pathology and Medicine
Yale School of Medicine
Director, Translational Immuno-oncology Laboratory
Yale Cancer Center
New Haven, Connecticut

Kurt Schalper, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb; Merck & Co., Inc.; Navigate BioPharma; Onkaido Therapeutics/Moderna Therapeutics; Pierre Fabre; Surface Oncology; TESARO, Inc.; and Vasculox, Inc./Tioma Therapeutics.
Consultant and/or Advisor for Celgene Corporation; Moderna Therapeutics; and Shattuck Labs.
Kurt Schalper, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations and/or cancer immunotherapy biomarker testing platforms.

Edward B. Garon, MD, MS
Director, Thoracic Oncology Program
Health Sciences Associate Professor
Department of Medicine, Division of Hematology-Oncology
UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.
Edward B. Garon, MD, MS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations and/or cancer immunotherapy biomarker testing platforms.

CME/MOC Reviewers

Kaushal Patel, MD

Kaushal Patel, MD, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C

Tracy L. Greene, MSN, RN, FNP-C, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
The activity titled “Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution” has been registered to offer 1.0 Lifelong Learning (Part II) credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath MOC credit. Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Individual or aggregated participant data may be shared with the funder of the activity.

Providership


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.